771 results on '"Giesel, Frederik L."'
Search Results
2. The Predictive Role of Metabolic Volume Segmentation Compared to Semiquantitative PET Parameters in Diagnosis of LVAD Infection using [18F]FDG Imaging
3. Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer
4. Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis
5. FAP-Liganden – Potenziale in der nuklearmedizinischen Bildgebung und Theranostik
6. PSMA in Diagnostik und Therapie
7. Delta-radiomics features of ADC maps as early predictors of treatment response in lung cancer
8. The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer
9. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
10. 2,5-Dimethoxy-4-iodoamphetamine and altanserin induce region-specific shifts in dopamine and serotonin metabolization pathways in the rat brain
11. 5-HT1A and 5-HT2A receptor effects on recognition memory, motor/exploratory behaviors, emotionality and regional dopamine transporter binding in the rat
12. Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides
13. Expression of fibroblast activation protein in intrathoracic solitary fibrous tumor
14. The impact of FAP imaging in lung cancer and beyond: a new chapter
15. Epithelioid granuloma mimicking lung cancer showed intense uptake on [18F]FAPI-74 PET
16. Comparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
17. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial
18. Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE Trial
19. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients
20. 68Ga- or 18F-FAPI PET/CT—what it can and cannot
21. Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound
22. The 5-HT1A receptor agonist 8-OH-DPAT modulates motor/exploratory activity, recognition memory and dopamine transporter binding in the dorsal and ventral striatum
23. Strengths and Weaknesses of Non-Enhanced and Contrast-Enhanced Cadaver Computed Tomography Scans in the Teaching of Gross Anatomy in an Integrated Curriculum
24. Current Status of Fibroblast Activation Protein Imaging in Gynecologic Malignancy and Breast Cancer
25. Fibroblast Activation Protein Inhibitor PET/CT in Gastric Cancer
26. Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical Translation
27. Activated fibroblasts in muscle sarcoidosis revealed by [18F]FAPI-74 PET
28. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
29. [68 Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease
30. Preclinical Evaluation of Biodistribution and Toxicity of [211At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer
31. A Role of Non-FDG Tracers in Lung Cancer?
32. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.
33. Advancement and Future Perspective of FAPI PET/CT In Gynecological Malignancies
34. A Role of PET/MR in Breast Cancer?
35. Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients.
36. Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
37. High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics
38. 68Ga-FAPI-PET/CT in patients with various gynecological malignancies
39. 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation
40. The Role of Fibroblast Activation Protein Ligands in Oncologic PET Imaging
41. Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of 68Ga-FAPI PET/CT
42. High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
43. Preclinical Evaluation of Biodistribution and Toxicity of [ 211 At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer.
44. Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer.
45. Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis.
46. [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
47. The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer
48. The impact of FAP imaging in lung cancer and beyond: a new chapter
49. Epithelioid granuloma mimicking lung cancer showed intense uptake on [18F]FAPI-74 PET
50. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.